Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more

Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question

On heels of ImmunoGen deal, pharma looks to Pfizer spinout led by Coles, Renaud to add neuroscience candidates nearing clinical readouts

Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role